Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

The preliminary results of the trial were reported for the pre-planned number of non-squamous patients ( N =55), demonstrating significant difference in PFS between VeriStrat Good and Poor patients overall and in the Carbo/Pem subgroup; however, in the Cis/Pem subgroup the difference did not reach statistical significance ( Grossi et al , 2014 ).

also in 111,027 other papers